Literature DB >> 2831737

Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats.

S V Shah1.   

Abstract

We examined the effect of scavengers of reactive oxygen metabolites on proteinuria in the passive Heymann nephritis model of membranous nephropathy. Passive Heymann nephritis was induced by a single intravenous injection of anti-Fx1A IgG in a dose of 10 mg/100 g body weight. Superoxide dismutase, a scavenger of superoxide or catalase which destroys hydrogen peroxide, did not affect the proteinuria. In contrast, dimethylthiourea (DMTU, 500 mg/kg followed by 125 mg/kg ip twice a day), a scavenger of hydroxyl radical, markedly reduced the proteinuria (day 5: anti-Fx1A 53 +/- 13, n = 18; anti-Fx1A + DMTU, 21 +/- 6 mg/24 h, n = 15, P less than 0.001). Experiments with 125I-labeled anti-Fx1A antibody demonstrated that DMTU did not affect the amount of antibody deposited in the kidney. Semiquantitative estimation of IgG and complement deposition in the kidney showed no differences between the DMTU-treated and control rats. A second hydroxyl radical scavenger, sodium benzoate (150 mg/kg ip twice a day), also resulted in marked reduction in proteinuria (day 5: anti-Fx1A 56 +/- 7, n = 9; anti-Fx1A + benzoate, 14 +/- 4 mg/24 h, n = 8, P less than 0.01). Because of the participation of iron in biological systems to generate hydroxyl radical, we also examined the effect of deferoxamine (DFO, 35 mg/day), an iron chelator, on the anti-Fx1A-induced proteinuria. There was a significant reduction in proteinuria in rats treated concurrently with DFO (day 5: anti-Fx1A 67 +/- 13, n = 15; anti-Fx1A + DFO, 29 +/- 4 mg/24 h, n = 15, P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831737     DOI: 10.1152/ajprenal.1988.254.3.F337

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  25 in total

1.  Preventive effects of hyperbaric oxygen treatment on glycerol-induced myoglobinuric acute renal failure in rats.

Authors:  Suleyman Ayvaz; Burhan Aksu; Mehmet Kanter; Hafize Uzun; Mustafa Erboga; Alkin Colak; Umit Nusret Basaran; Mehmet Pul
Journal:  J Mol Histol       Date:  2012-02-07       Impact factor: 2.611

Review 2.  Molecular development of immune deposits and proteinuria in Heymann nephritis.

Authors:  D Kerjaschki
Journal:  Clin Investig       Date:  1993-10

Review 3.  Reactive oxygen molecules, oxidant injury and renal disease.

Authors:  S P Andreoli
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

4.  Oxidation of the mesangial matrix metalloproteinase-2 impairs gelatinolytic activity.

Authors:  J Mattana; L Margiloff; P Sharma; P C Singhal
Journal:  Inflammation       Date:  1998-06       Impact factor: 4.092

Review 5.  Mechanisms of immune-deposit formation and the mediation of immune renal injury.

Authors:  Masaomi Nangaku; William G Couser
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

6.  Reactive oxygen species cause direct damage of Engelbreth-Holm-Swarm matrix.

Authors:  B Riedle; D Kerjaschki
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

Review 7.  Membranous nephropathy. Insights from Heymann nephritis.

Authors:  T Cavallo
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

8.  Visceral glomerular epithelial cells can proliferate in vivo and synthesize platelet-derived growth factor B-chain.

Authors:  J Floege; R J Johnson; C E Alpers; S Fatemi-Nainie; C A Richardson; K Gordon; W G Couser
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

9.  Iron, oxidative stress, and clinical outcomes.

Authors:  Rajiv Agarwal
Journal:  Pediatr Nephrol       Date:  2007-11-21       Impact factor: 3.714

10.  Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis.

Authors:  T J Neale; R Ullrich; P Ojha; H Poczewski; A J Verhoeven; D Kerjaschki
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.